Hepatitis C Virus – Epidemiology – Mature Markets Data
DRG Epidemiology's coverage of hepatitis C comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of hepatitis C for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's hepatitis C forecast will answer the following questions:
- Of all people with hepatitis C, how many in each country across the world have been formally diagnosed?
- Of all people diagnosed with hepatitis C, how many in each country across the world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hepatitis C over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following hepatitis C patient populations:
- Total Prevalent Cases by Viremic Status
- Diagnosed Prevalent Cases Drug Treatment subpopulation(s)
- Hepatitis C Total Incident Cases Total Prevalent Cases Diagnosis subpopulation(s)
- Hepatitis C Total Prevalent Cases
Note: coverage may vary by country and region.
Table of contents
- Hepatitis C Virus - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Total Prevalence of Hepatitis C Virus per 1,000 per Year Among People of All Ages in 2021 and 2041ttttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of HCV over the Next 20 Yearsttttttttttttttttt
- Analysis of the Viremic Prevalent Cases of HCV in 2021 by Genotypettttttttt
- Total Prevalence of Hepatitis C Virus per 1,000 per Year Among People of All Ages in 2021 and 2041ttttttttttttttt
- Total Prevalence of Hepatitis C Virus per 1,000 per Year Among People of All Ages in 2021 and 2041ttttttttttttttt
- Total Prevalence of Hepatitis C Virus per 1,000 per Year Among People of All Ages in 2021 and 2041ttttttttttttttt
- Key Findings
- Epidemiology Data
- Methods
- Total Seroprevalent Cases
- Total Incident Cases
- Total Prevalent Viremic Cases
- HCV Genotype Prevalence
- Cirrhotic Status by Genotype
- Diagnosed Prevalent Cases
- Drug-Treated Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of HCV
- Studies Excluded from the Analysis of HCV
- Risk/Protective Factors
- Risk/Protective Factors for HCV
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.